Blood test could spot bladder cancer spread early, guiding immunotherapy
NCT ID NCT04138628
First seen Mar 04, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests whether starting immunotherapy early, based on a sensitive blood test that finds tumor DNA, can better control metastatic bladder cancer after bladder removal surgery. About 154 adults with signs of cancer in their blood, with or without visible tumors on scans, will receive the treatment. The goal is to see if this approach leads to complete response and helps identify who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aalborg Universitetshospital
Aalborg, 9100, Denmark
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Herlev Hospital
Herlev, 2730, Denmark
-
Odense Universitetshospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.